SCHEMBL19481817

SCHEMBL19481817

CCN1CCC(COc2ccc(-c3cc4c(N5CCN(C(=O)C6CC6)CC5)ccnn4c3)cc2)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1B P49286 2/20 0.40
MAPT P10636 6/20 0.39
MAPK1 P28482 2/20 0.39
PKM P14618 1/20 0.39
RET P07949 3/20 0.39
KIT P10721 1/20 0.38
TP53 P04637 4/20 0.38
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
LMNA P02545 4/20 0.37
KDM4E B2RXH2 6/20 0.37
ALDH1A1 P00352 3/20 0.37
TDP1 Q9NUW8 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
THRB P10828 1/20 0.37
HTT P42858 1/20 0.37
HSD17B10 Q99714 1/20 0.37
POLB P06746 1/20 0.37
ALOX15 P16050 1/20 0.37
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19481765 0.95 MAPT (0.40) MTNR1BMAPTMAPK1PKMRET
SCHEMBL20820700 0.88 MAPT (0.41) MAPTMAPK1KITTP53LMNA
SCHEMBL19481774 0.87 KIT (0.40) MTNR1BMAPTMAPK1PKMRET
SCHEMBL19481686 0.86 CYP4F2 (0.40) MTNR1BMAPTMAPK1PKMRET
SCHEMBL19458935 0.85 TUBB4A (0.47) MTNR1BMAPK1RETCYP4F2CYP4A11
SCHEMBL19481751 0.85 MTNR1B (0.39) MTNR1BMAPTMAPK1PKMRET
SCHEMBL19481814 0.85 KIT (0.41) MTNR1BMAPTRETKITTP53
SCHEMBL19481716 0.85 KIT (0.41) MTNR1BMAPTMAPK1PKMRET
SCHEMBL19481701 0.85 KIT (0.38) MAPTMAPK1RETKITTP53
SCHEMBL19481699 0.85 KIT (0.38) MAPTMAPK1RETKITTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3442977-B1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORP (US) 2023-06-28 EP disclosed
US-11634422-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2023-04-25 US disclosed
US-10669277-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2020-06-02 US disclosed
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2020-01-30 US disclosed
US-10233186-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2019-03-19 US disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 US disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 US disclosed
WO-2017181117-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION (US) 2017-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10669277-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 MTNR1B 2867/4885MAPT 3886/4885MAPK1 652/4885
US-20200031830-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 MTNR1B 2867/4885MAPT 3886/4885MAPK1 652/4885
US-11634422-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 MTNR1B 2867/4885MAPT 3886/4885MAPK1 652/4885
US-10233186-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 MTNR1B 3261/4885MAPT 3683/4885MAPK1 520/4885
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 MTNR1B 2867/4885MAPT 3886/4885MAPK1 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.